- Home
- ARI vs PHVS Comparison
ARI vs PHVS Comparison
Compare ARI & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARI
- PHVS
- Stock Information
- Founded
- ARI 2009
- PHVS 2015
- Country
- ARI United States
- PHVS Switzerland
- Employees
- ARI N/A
- PHVS N/A
- Industry
- ARI Real Estate Investment Trusts
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- ARI Real Estate
- PHVS Health Care
- Exchange
- ARI Nasdaq
- PHVS Nasdaq
- Market Cap
- ARI 1.1B
- PHVS 980.9M
- IPO Year
- ARI 2009
- PHVS 2021
- Fundamental
- Price
- ARI $9.73
- PHVS $23.00
- Analyst Decision
- ARI Hold
- PHVS Buy
- Analyst Count
- ARI 5
- PHVS 6
- Target Price
- ARI $10.08
- PHVS $37.17
- AVG Volume (30 Days)
- ARI 1.4M
- PHVS 71.6K
- Earning Date
- ARI 07-29-2025
- PHVS 08-13-2025
- Dividend Yield
- ARI 10.29%
- PHVS N/A
- EPS Growth
- ARI N/A
- PHVS N/A
- EPS
- ARI N/A
- PHVS N/A
- Revenue
- ARI $276,844,000.00
- PHVS N/A
- Revenue This Year
- ARI $32.11
- PHVS N/A
- Revenue Next Year
- ARI $19.41
- PHVS N/A
- P/E Ratio
- ARI N/A
- PHVS N/A
- Revenue Growth
- ARI 104.64
- PHVS N/A
- 52 Week Low
- ARI $7.70
- PHVS $11.51
- 52 Week High
- ARI $11.20
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- ARI 44.67
- PHVS 70.21
- Support Level
- ARI $9.80
- PHVS $21.84
- Resistance Level
- ARI $10.04
- PHVS $24.41
- Average True Range (ATR)
- ARI 0.17
- PHVS 1.74
- MACD
- ARI -0.02
- PHVS 0.54
- Stochastic Oscillator
- ARI 35.45
- PHVS 76.27
About ARI Apollo Commercial Real Estate Finance Inc
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.